Overview

A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors

Status:
Unknown status

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

This study is to assess the safety, tolerability and pharmacokinetics of single dose and multiple doses of humanized anti-VEGF monoclonal antibody (Sevacizumab) in patients with advanced or metastatic solid tumors. The secondary objective is to explore the preliminary anti-tumor effects.

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Treatments:

Antibodies
Antibodies, Monoclonal
Bevacizumab